By lowering the expression of target genes, such as those involved in inflammation (e.g., adiponectin, (TNF-α), leptin, and TLR 4), obesity treatment leads to the prevention of NF-kB activation (Kasprzak-Drozd et al., 2022). The gene discussed is NFKB1; the disease is obesity due to melanocortin 4 receptor deficiency.